Is BLCO a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Bausch + Lomb (BLCO) rests on Margin and EBITDA expansion: After years of underearning, Bausch + Lomb has been driving structural cost changes and pricing discipline. The bear case rests on the dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Analysts covering it publish targets from $16.00 to $21.00 against a $16.55 price, so even the professionals disagree by 27% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and lens-care solutions plus consumer eye drops such as LUMIFY and PreserVision supplements), Pharmaceuticals (around 25%, led by the dry-eye drug MIEBO and international brands), and Surgical (about 18%, including intraocular lenses, phacoemulsification systems and cataract and retina instruments). Full-year 2025 revenue reached roughly $5.1 billion, and the company sells into the structurally growing markets of an aging population, rising myopia and expanding cataract volumes. The investment picture is a mix of genuine operating improvement and unresolved corporate complexity. Q1 2026 revenue grew about 9% year over year to roughly $1.24 billion with adjusted EBITDA nearly doubling, prompting management to raise full-year guidance. At the same time, Bausch + Lomb remains roughly 88% owned by heavily indebted parent Bausch Health, whose long-delayed separation (via spin-off or outright sale) continues to cap the valuation. Layered on top are the residual effects of the 2025 enVista intraocular-lens recall and the company's own leverage, making this a name where the story matters as much as the numbers.
The bull case: what would have to be true for $21.00
The most optimistic published target on BLCO is $21.00, +26.9% from the $16.55 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Margin and EBITDA expansion
After years of underearning, Bausch + Lomb has been driving structural cost changes and pricing discipline. Q1 2026 adjusted EBITDA rose roughly 59% year over year, and management raised full-year adjusted EBITDA guidance toward the $1.01 to $1.06 billion range, signaling that the profitability inflection may be durable rather than a one-off.
2. Pharmaceuticals and MIEBO ramp
The pharmaceuticals segment posted the fastest growth in early 2026, led by the dry-eye drug MIEBO and international brands. Dry-eye disease is a large, underserved market, and continued MIEBO uptake gives the company a branded growth engine to offset slower U.S. generics.
3. Secular eye-care demand and surgical recovery
An aging global population, rising rates of myopia and growing cataract-surgery volumes support steady demand across contact lenses and surgical devices. The enVista intraocular-lens franchise returned to full production and reached pre-recall sales levels by late 2025, restoring its role in the premium IOL segment.
4. Separation catalyst from Bausch Health
Bausch Health still owns the large majority of BLCO and has explored both a spin-off and a sale for years. A clean separation, if it clears solvency hurdles, could remove the control discount and let BLCO trade closer to eye-care peers, though timing remains uncertain.
The bear case: what would have to be true for $16.00
The most pessimistic published target is $16.00, -3.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Bausch + Lomb is worth if the risks below bite instead of the drivers above.
The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Bausch + Lomb carries its own meaningful leverage (several billion dollars of debt), so rising rates or slower EBITDA growth would pressure the balance sheet. The 2025 enVista recall, tied to toxic anterior segment syndrome, is estimated to weigh on 2026 revenue by roughly $78 million and could linger as a brand and litigation risk. The company remains net-loss-making on a GAAP basis, and competition from far larger and better-capitalized rivals like Alcon, Johnson & Johnson and CooperVision is intense across every segment.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding BLCO already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on BLCO
12 analysts cover BLCO, with an average target of $18.38 (+11.1% against $16.55) and a split of 6 buy, 6 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the BLCO forecast and price target page.
How is BLCO valued? (as of July 2026)
Snapshot for BLCO as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$5.2B
- FY2026 revenue guidance: ~$5.42B to $5.52B
- Q1 2026 revenue: ~$1.24B (+9% YoY)
- FY2026 adj. EBITDA guidance: ~$1.01B to $1.06B
- Q1 2026 net loss: ~$71M (narrowed from ~$212M)
- Enterprise value: ~$10B
BLCO is not yet consistently GAAP-profitable, so investors lean on adjusted EBITDA and revenue growth rather than earnings multiples. Eye-care peers such as Alcon and The Cooper Companies have traded near 18 to 20 times EV/EBITDA, versus a lower multiple for BLCO that reflects the Bausch Health control discount and leverage. Closing that gap depends heavily on the separation resolving and margins continuing to expand.
How do you decide if BLCO is a buy?
Rather than asking whether BLCO is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BLCO indirectly through an index or sector ETF before adding more.
What would change your mind on BLCO
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Margin and EBITDA expansion stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the BLCO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BLCO against your real portfolio and see your actual exposure before deciding.
Investing in Bausch + Lomb with AI
Connect the broker you already use and ask Walnut's AI how BLCO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is BLCO a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Margin and EBITDA expansion, with revenue (ttm) at ~$5.2B. The bear case rests on the dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Analysts covering it are spread from $16.00 to $21.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell BLCO?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $16.00, -3.3% from the $16.55 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for BLCO?
+
Margin and EBITDA expansion. After years of underearning, Bausch + Lomb has been driving structural cost changes and pricing discipline. The most optimistic analyst target on BLCO is $21.00, +26.9% from the $16.55 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for BLCO?
+
The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Bausch + Lomb carries its own meaningful leverage (several billion dollars of debt), so rising rates or slower EBITDA growth would pressure the balance sheet. The 2025 enVista recall, tied to toxic anterior segment syndrome, is estimated to weigh on 2026 revenue by roughly $78 million and could linger as a brand and litigation risk. The company remains net-loss-making on a GAAP basis, and competition from far larger and better-capitalized rivals like Alcon, Johnson & Johnson and CooperVision is intense across every segment. The most pessimistic published target is $16.00, -3.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Bausch + Lomb do?
+
Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and
What would have to change for BLCO to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Margin and EBITDA expansion) stalling in the reported numbers rather than in the narrative, the risk above (the dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Bausch + Lomb (BLCO) do?
+
It is a global eye-health company selling contact lenses, lens-care solutions and consumer eye drops (Vision Care), prescription eye medicines like the dry-eye drug MIEBO (Pharmaceuticals), and cataract, retina and other surgical devices including intraocular lenses (Surgical).
Is BLCO profitable?
+
BLCO is growing revenue and adjusted EBITDA quickly, but it still reports GAAP net losses. Q1 2026 revenue rose about 9% to roughly $1.24 billion while the net loss narrowed to about $71 million from roughly $212 million a year earlier.
Why does BLCO trade at a discount to eye-care peers?
+
Bausch + Lomb is roughly 88% owned by heavily indebted parent Bausch Health, whose long-delayed separation and about $20 billion of consolidated debt create a control overhang and forced-seller risk that peers such as Alcon and CooperVision do not carry.
Walnut is informational, not investment advice, and gives no verdict on BLCO. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.